These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 14632593)
1. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Tanvetyanon T; Nand S Ann Pharmacother; 2003 Dec; 37(12):1818-20. PubMed ID: 14632593 [TBL] [Abstract][Full Text] [Related]
2. Desensitization to imatinib in patients with leukemia. Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754 [TBL] [Abstract][Full Text] [Related]
3. Livedoid skin reaction probably due to imatinib therapy. Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842 [TBL] [Abstract][Full Text] [Related]
4. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824 [TBL] [Abstract][Full Text] [Related]
5. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Severino G; Chillotti C; De Lisa R; Del Zompo M; Ardau R Ann Pharmacother; 2005 Jan; 39(1):162-4. PubMed ID: 15546944 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650 [TBL] [Abstract][Full Text] [Related]
7. [A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate]. Nakatani K; Tanabe S; Nishimura K; Shimoda T; Azuma M; Katada C; Sasaki T; Higuchi K; Koizumi W; Saigenji K Gan To Kagaku Ryoho; 2006 Jul; 33(7):997-1000. PubMed ID: 16835496 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435 [TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. Hsieh HJ; Chan AL; Lin SJ Chemotherapy; 2009; 55(4):197-9. PubMed ID: 19439939 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830 [TBL] [Abstract][Full Text] [Related]
11. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia. Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930 [No Abstract] [Full Text] [Related]
14. [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy]. Sumi M; Tauchi T; Shimamoto T; Sshida G; Nakajima A; Ito Y; Ohyashiki K Rinsho Ketsueki; 2002 Sep; 43(9):868-70. PubMed ID: 12412295 [TBL] [Abstract][Full Text] [Related]
15. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Quintas-Cardama A; Kantarjian H; O'Brien S; Garcia-Manero G; Rios MB; Talpaz M; Cortes J Cancer; 2004 Jun; 100(12):2592-7. PubMed ID: 15197801 [TBL] [Abstract][Full Text] [Related]
16. Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour. Cheng H; Geist DE; Piperdi M; Virk R; Piperdi B Australas J Dermatol; 2009 Feb; 50(1):41-3. PubMed ID: 19178491 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636 [TBL] [Abstract][Full Text] [Related]
18. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism. Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138 [No Abstract] [Full Text] [Related]
19. [Imatinib-induced purpuric vasculitis]. Hamm M; Touraud JP; Mannone L; Klisnick J; Ponnelle T; Lambert D Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):765-7. PubMed ID: 14576606 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients. Kobayashi S; Kimura F; Kobayashi A; Sato K; Motoyoshi K Ann Hematol; 2009 Apr; 88(4):311-5. PubMed ID: 18704417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]